Laekna Announces Clinical Collaboration with Lilly to Develop LAE102 Monoclonal Antibody for the Treatment of Obesity
Laekna Announces Clinical Collaboration with Lilly to Develop LAE102 Monoclonal Antibody for the Treatment of Obesity
11/20/24, 3:50 PM
Location
los angelesIndustry
biotechnology
health care
Type
partnership
Laekna, Inc. has announced a clinical collaboration with Eli Lilly and Company to develop LAE102, an ActRIIA antagonistic mAb as a novel treatment for obesity. The collaboration will focus on the clinical evaluation of LAE102, which may have potential as a first-in-class therapy in this disease area.
Company Info
Location
los angeles, california, united states
Additional Info
Laekna, Inc. (2105.HK) is a global biotech company focused on novel drug development for metabolic and cancer diseases. Eli Lilly and Company is a global leader in cardiometabolic health, including diabetes and obesity.